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Abstract
Background: Hepatoma-derived growth factor (HDGF) is a nuclear protein that is a mitogen for a wide variety of
cells. Mass spectrometry based methods have identified HDGF as a phosphoprotein without validation or a
functional consequence of this post-translational modification.
Results: We found that HDGF in primary mouse aortic vascular smooth muscle cells (VSMC) was phosphorylated.
Wild type HDGF was phosphorylated in asynchronous cells and substitution of S103, S165 and S202 to alanine
each demonstrated a decrease in HDGF phosphorylation. A phospho-S103 HDGF specific antibody was developed
and demonstrated mitosis-specific phosphorylation. HDGF-S103A was not mitogenic and FACS analysis
demonstrated a G2/M arrest in HDGF-S103A expressing cells, whereas cells expressing HDGF-S103D showed cell
cycle progression. Nocodazole arrest increased S103 phosphorylation from 1.6% to 29% (P = 0.037).
Conclusions: Thus, HDGF is a phosphoprotein and phosphorylation of S103 is mitosis related and required for its
function as a mitogen. We speculate that cell cycle regulated phosphorylation of HDGF may play an important role
in vascular cell proliferation.
Background
HDGF [GenBank: NM_004494] is a heparin binding pro-
tein originally isolated from conditioned media of a
human hepatoma (HuH-7) cell line. HDGF was subse-
quently shown to be a mitogen for many cell types with
nuclear localization necessary for its mitogenic activity
[1-6]. Expression of HDGF is developmentally regulated in
at least the renal, cardiovascular and pulmonary systems
[1,3,7] and re-expressed at least in the both the lung [8]
and the arterial wall in response to injury [9], suggesting a
role in tissue repair. HDGF has also been identified at
least as an important prognostic marker in pathologic cell
growth, as it is overexpressed in a number of cancers with
expression linked to a poor outcome in lung, esophageal,
pancreatic and hepatic cancer [10-13].
Many nuclear proteins undergo post-translational modi-
fication to regulate their activity. This is most clearly
demonstrated by the cell cycle regulatory cyclin and CDK
proteins which undergo both phosphorylation and depho-
sphorylation to regulate their activity [reviewed in [14]].
Previously we had shown by two-dimensional gel electro-
phoresis that HDGF in human melanoma cells has multi-
ple isoforms that migrated with the same mass in SDS but
had different pI [15], suggesting post-translational modifi-
cations, such as phosphorylation. In addition, in a proteo-
mic screen for phosphorylated nuclear proteins, HDGF
w a si d e n t i f i e db ym a s ss p e c t r o m e t r yt oh a v em u l t i p l e
phosphorylated serines [16,17]. Whether HDGF is indeed
phosphorylated in vivo, and whether phosphorylation
affects HDGF function are all unknown.
In the present study, we detail that HDGF is indeed a
phosphoprotein, identify S103 as a significant phosphor-
ylation site and demonstrate that phosphorylation of




HEK-293T, MDA-MB231 and COS-7 cells were obtained
from ATCC (Manassas, VA). Low passage mouse pri-
mary aortic vascular smooth muscle cells (VSMC) were
isolated as previously described [1] and all lines main-
tained in DMEM supplemented with 10% fetal bovine
serum (Gibco) at 37°C in 5% CO2. For proliferation
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then incubated overnight with BrdU (10 μM, Roche
Diagnostics, Indianapolis, IN). For cell cycle arrest stu-
dies, MDA-MB231 cells were seeded at 10
5 cells/ml in
6 well dishes containing a cover slip and DMEM with
10% serum. After 8 h cells were left in serum free (0.5%
serum) media for overnight. Next morning cells were re-
stimulated with 10% FCS. After 8 h cells were treated
with or without 200 nM nocodazole for next 16 h. Next
morning cells were briefly washed with ice cold PBS and
fixed with 4% formaldehyde in DPBS.
Plasmids and transfections
Full length wild type rat HDGF was cloned in pK7-GFP
and pKH3 (vectors were gifts of Ian Macara, University of
Virginia) [4] and substitution of serine (S) 103, 165 and
202 to alanine (A) or aspartic acid (D) was done using
PCR (QuickChange Site Directed Mutagenesis, Strata-
gene). 1 × 10
6 HEK-293T, COS-7 or VSMC cells were
plated in 60 mm dishes and transfected the following day
with 4 ug of plasmid DNA using calcium phosphate (Pro-
Fection Mammalian Transfection System-Calcium Phos-
phate, Promega, WI) or FuGene (Roche Applied Science)
according to the manufacturers’ recommendations.
Fluorescent activated cell sorting
HEK-293T cells were transfected as above to express
G F Po rG F P - H D G Ff u s i o n s .3 6h o u r sa f t e rt r a n s f e c t i o n
cells were processed for cell cycle FACS analysis with
gating for no GFP and GFP after the method of Schmid
and Sakamoto [18] (Becton Dickinson FACSCalibur Dual
Laser) using ModFit LT software (Verity Software, Top-
sham, ME). Cell cycle analysis was expressed as percent
in G1, G2 and S. Each FACS analysis was performed in
triplicate with the results pooled from 4-5 separate
experiments.
Antibodies and immunoblotting
Anti-phospho-S103-HDGF was generated by Biosource
(Hopkington MA) using a synthetic phosphopeptide
corresponding to amino acids 95-107 of human HDGF
with an N-terminal cysteine (CVKASGYQS(pS)QKKS)
for coupling to keyhole limpet hemocyanin.
Western blot analysis was performed as previously
described [1,4,7]. Briefly, phosphorylated proteins were
enriched from 4 × 10
6 COS-7 cells using the Phospho-
Protein Purification Kit (Qiagen, Valencia, CA) following
the manufacturers instructions. For immunoblot analysis,
COS-7 whole cell lysates and isolated proteins (20 μg)
were separated by 10% SDS-PAGE and transferred to
Trans-Blot Transfer Medium (Bio-Rad, Hercules, CA).
Blots were blocked in TBS-T (0.1% Tween, w/v) and 5%
bovine albumin (Roche) for one hour and probed with
either anti-phospho-S103-HDGF (1:500) or anti-HDGF
(1:1000) in TBS-T for 1 hour at room temperature. After
washing with TBS-T membranes were incubated with an
anti-rabbit secondary antibody coupled to horseradish
peroxidase (1/30,000). After washing, the blots were
developed using enhanced chemiluminescence (GE
Healthcare).
Immunocytochemistry
Immunocytochemical analysis was performed as previously
described [1,4,7]. Briefly, COS-7 cells grown on glass cover-
slips in six well plates were fixed in 4% buffered parafor-
maldehyde for 30 minutes at room temperature then
washed with cold PBS. Separate coverslips were incubated
with the anti-HDGF (1:2000) or anti-phospho-S103-HDGF
(1:250). Control coverslips were incubated with no primary
antibody or preabsorbed primary antibody with 1 μgo ft h e
S103 phosphopeptide described above at the same concen-
tration as the primary antibody. For BrdU detection, cells
were fixed in 2% paraformaldehyde for 10 minutes at room
temperature, with BrdU detected using a mouse monoclo-
nal anti-BrdU antibody (6 ug/ml, Roche). Vector Red
(Vector Laboratories) was used as a fluorescent substrate
to identify specific HDGF or BrdU staining and DAPI as a
specific DNA counterstain. Images were acquired on a
Nikon Eclipse 400 microscope equipped with a MicroPubl-
isher digital camera (Qimaging, Burnaby, BC, Canada)
and merged using Adobe Photoshop cs software (Adobe
Systems Inc., San Jose, CA). For nocodazole cell cycle
arrest studies, MDA-MB231 cells were immunostained for
anti-phospho-S103-HDGF and fluorescent microscope
acquired images analyzed by Nikon NIS-element software.
The total number of cells was counted by detecting size
and intensity of DAPI staining. The number of phospho-
S103 positive cells was identified as having at least 10 times
more intense staining than non-treated control cells. Cells
were counted from at least 3 different fields per coverslip
for each experiment with a total of 3 individual experi-
ments performed. Results were expressed as percent of
phospho-S103-HDGF positive nuclei analyzed using a
non-paired t-test with a P value of < 0.05 considered as
significant.
Results
HDGF is a phosphoprotein
Previously we found multiple forms of HDGF by 2D gels
and suspected this was due to a post-translational modifi-
cation such as phosphorylation that could change the pI
of the protein. The NetPhosK 1.0 computer algorithm
[19] using statistical ranking identified S103 as the most
likely candidate site for phosphorylation (Score 0.86).
In addition, S165 and S202 were recently identified as
phosphorylation sites in HDGF by mass spectrometry of
HeLa nuclear and HT-29 cell extracts [16,17]. Sequence
comparisons confirmed that S103, S165 and S202 are
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were transfected to express GFP fusions of wild type
HDGF or S103A, S165A or S202A substitution HDGF
polypeptides and metabolically radiolabeled with [
32P]
orthophosphate for 2 hours. The tagged proteins were
recovered by anti-GFP immunoprecipitation and as
shown in Figure 1, HDGF wt was phosphorylated and
phosphorylation of the S103A, S165A and S202A were
reduced relative to wild type (Figure 1) demonstrating
that all three of these serines were kinase substrates.
HDGF S103 is phosphorylated during mitosis
To further explore HDGF S103 phosphorylation we devel-
oped a phospho-S103-HDGF antibody. Western blotting
of enriched COS-7 phosphoproteins demonstrated detec-
tion of S103-HDGF phosphorylation (Figure 2). The phos-
pho-S103-HDGF antibody identified both the high and
low mass HDGF protein bands from the same COS-7 cell
lysate detected with a wild type HDGF antibody [1]. With
the phospho-S103 HDGF antibody, the higher mass
HDGF band was less distinct compared to the lower mass
band, but obvious with longer exposure. To map the
expression of S103-HDGF, we immunostained COS-7
cells with both total and phospho-S103-HDGF antibodies
(Figure 3A-C). Using the total HDGF antibody and COS-7
cells, HDGF was highly expressed in 81.4% of nuclei and
with the phospho-S103-HDGF antibody, only 5.4% of cell
nuclei were immuno-positive (Figure 3A). Of interest, the
nuclei positive for phospho-S103-HDGF were all under-
going mitosis (Figure 3B), based on the condensed chro-
matin. Importantly preabsorbing the antibody with the
target phosphopeptide, or the absence of the primary anti-
body in the immunostaining reaction demonstrated that
staining was specific (Figure 3B). Further study (Figure 4)
revealed that phospho-S103-HDGF was only detected dur-
ing mitosis. Phospho-S103-HDGF was first detectable at
the time of nuclear condensation and breakdown of the
nuclear envelope, peaks at metaphase with alignment of
chromosomes along the metaphase plate and disappears
with daughter cell separation in anaphase. This was also
evident when we cell cycle arrested cells with nocodazole
and stained those cells with the phospho-S103-HDGF
antibody (Figure 5). Nocodazole mitotic arrest significantly
increased the number of phospho-S103-HDGF positive
cells when compared to controls (29% vs 1.6%, P = 0.037,
respectively).
Phosphorylation of S103 is necessary for HDGF mitogenic
function
HDGF is a potent mitogen for VSMC [1]. To examine
the role of HDGF S103 phosphorylation in function as a
mitogen, mouse VSMC were transfected to express GFP-
HDGF S103A. Cells were serum starved for 24 hours
then pulse-labeled with BrdU. BrdU incorporation (red)
into DNA (blue) by transfected (green) cells was detected
by fluorescent immunocytochemistry. As shown in
Figure 6, HDGF-S103A traffics normally to the nucleus,
Figure 1 HDGF is a phosphoprotein. Autoradiogram of HDGF
immunoprecipitated from COS-7 cells that transiently expressed
wild type rat GFP-HDGF (WT-HDGF) or S103A, S165A, or S202A-
HDGF substitution mutations after in vivo [
32P] orthophosphate
labeling for two hours, and resolution by SDS-PAGE.
Figure 2 Phospho-S103-HDGF Immunoblotting.W e s t e r nb l o to f
COS-7 whole cell lysate (25 ug, Cell lysate), cell lysate PhosphoProtein
column flow through (25 ug) or PhosphoProtein column bound
proteins (25 ug, Po4 proteins, PhosphoProtein Purification Kit, see
Methods) using a specific anti-phospho-S103-HDGF (top panel, A) or
pan-anti-HDGF (bottom panel, B). Arrows = the high and low
molecular weight bands in the Po4 protein lane with both antibodies.
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Page 3 of 9Figure 3 Phospho-S103-HDGF expression in mitotic nuclei.( A )C O S - 7c e l l sw e r ei m m u n o s t a i n e dfor HDGF or phospho-S103-HDGF and
percentage positive cells determined. (B) Immunostaining of COS-7 cells (red) for total HDGF and middle panel for phospho-S103-HDGF. (C)
Staining specificity was proven by pre-absorbing the phospho-S103-HDGF antibody with the S103 phosphopeptide (Pre-Ab) or omission of the
phopho-S103 HDGF antibody (No primary). Cells were counterstained with DAPI to identify the nucleus and DNA.
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for nuclear translocation or retention. However as shown
in Figure 6, HDGF-S103A did not stimulate BrdU incor-
poration, showing it was not acting as a mitogen.
Phosphorylation of HDGF S103 is necessary for cell cycle
progression
To test for a possible role of phosphorylation in HDGF
function, S103 was mutated to an aspartic acid (S103D)
as a phospho-mimic residue. The effect of HDGF-
S103D on cell proliferation was tested with asynchro-
nous HEK-293 cells transfected to express, GFP fused to
wild type HDGF, HDGF S103A or S103D and cell cycle
analysis performed by FACS on the GFP positive cells
and the GFP negative cells from the same sample as a
control. As shown in Figure 7A, consistent with HDGF
being a growth factor, HDGF significantly decreased the
percentage of cells in G1 (43.3 ± 1.3% vs 49.6 + 3.0%,
P < 0.009) and increased the percentage in G2 (19.0 ±
1.8% vs 11.4 ± 1.1%, P < 0.004) as compared to GFP.
Unlike HDGF, HDGF S103A did not decrease the cell
population in G1 (43.3 ± 1.3% and 49.6 ± 3.0% respec-
tively), or increase the fraction of cells in S+G2 (56.7 ±
3.2 and 50.4 ± 3.0%, respectively). In contrast to HDGF
S103A, HDGF S103D significantly decreased the fraction
of cells in G1 (49.4 ± 3.0% and 33.4 ± 3.8%, respectively)
Figure 4 HDGF S103 is phosphorylated during M phase of the cell cycle. (A) Representative immunostaining for phospho-S103 HDGF was
first detected in COS-7 cells that have undergone nuclear envelope breakdown and chromosomal condensation, (B) and in cells in metaphase
and early anaphase. (C and D) HDGF-S103 phosphorylation rapidly falls to undetectable levels as daughter cells separate in late anaphase and
telophase. Co-staining with DAPI demonstrates chromosomal DNA condensation in phospho-S103-HDGF immunostained cells (Merge).
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(50.4 ± 3.0% and 66.6 ± 3.8%, respectively). Therefore
expression of HDGF S103D, a phospho-mimic, was a
more potent mitogen than wild type HDGF and loss of
phosphorylation on S103 abrogated HDGFs mitogenic
function. This effect on the cell cycle was limited to
transfected cells as non-transfected cells from the same
plate demonstrated normal cell cycle proportions
(Figure 7B). This demonstrates that the effects on the
cell cycle were not transfection artifacts.
Discussion
HDGF is an abundant nuclear protein with activity as a
mitogen, in that it stimulates cell cycle progression. In
this study we demonstrate phosphorylation of S103 dur-
ing mitosis and show this phosphorylation is required
Figure 5 Phosphorylation of S103 HDGF is increased during mitotic phase of cell division.A .M D A - M B 2 3 1c e l l sw e r et r e a t e dw i t h o u t
(control) or with nocodazole (200 nM) to arrest the cell cycle at mitosis and immunostained with the anti-phospho-S103-HDGF antibody and
DAPI. B. Graph representing percentage of phospho-S103-HDGF positive cells in control and nocodazole treated cells (n = 3; p = 0.037
calculated by unpaired two-tailed T test).
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Page 6 of 9Figure 6 HDGF-S103A is not a mitogen. HDGF-GFP-S103A was expressed in mouse VSMC for 24 hours and cells labeled with BrdU overnight.
Cells were immunostained for BrdU as a marker of DNA replication and observed for co-localization of GFP and BrdU. A = cells expressing
HDGF-GFP-S103A, B = no staining for BrdU, C = DAPI staining to show that HDGF-GFP-S103A nuclear targeting is not affected.
Figure 7 Phosphorylation of HDGF S103 regulates its ability to stimulate cell proliferation. A. HDGF-GFP, HDGF-GFP-S103A or HDGF-GFP-
S103D fusion proteins were expressed in HEK-293 cells for 24 hours and the cell cycle analyzed in GFP and non-GFP expressing cells by FACS. (n
= 4-5, with three replicates for each experiment.) B. Cell cycle analysis of cells expressing the HDGF fusions (GFP) vs non-GFP positive cells from
the same experiments in A. # = HDGF vs GFP, * = HDGF-S103A or D vs HDGF. * and # = P ≤ 0.05.
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phorylation in vivo was suggested by the computer
search engine NetPhosK 1 [19] that matches amino acid
sequence to known protein kinase phosphorylation
motifs, with statistical ranking for significance. This type
of search engine is useful for identifying potential phos-
phorylation sites within a protein of interest. Separate
studies had identified HDGF as a phosphorylated
nuclear protein based on mass spectroscopy (MS)
[16,17] or by in vitro kinase assays [20]. These studies
indicated S132, S133, S165, T200 and S202 were phos-
phorylated in HeLa or HT-29 cells [16,17]. Our results
identify S103 as a new, previously unknown significant
HDGF phosphorylation site not previously identified by
MS. Because S103 is only phosphorylated during mito-
sis, based on immunostaining with a phospho-amino
acid specific antibody, this likely explains why pS103
was not found by MS in non-synchronized cells. This is
supported by the relatively low levels of pS103-HDGF
we observed by immunoblotting whole cell extracts. It is
also unclear from these global MS studies whether the
peptide containing S103 was detected. We demonstrate
that S165 and S202 are also phosphorylated in vivo, but
at possibly lower levels in COS-7 cells relative to S103,
based on differences in radiolabeling of the mutated
p r o t e i n s .I ti so fi n t e r e s tt h a tp r e v i o u s l yS 1 6 5h a db e e n
predicted to be a Cdk2 substrate based on sequence,
however mutation of S165 had no effect on the nuclear
targeting of HDGF or on its mitogenic activity [4,5].
Although the kinase for S103 is not known, Salvi et al
[20] have shown that HDGF can by phosphorylated in
vitro by casein kinase 2. It is not known whether S132/
133 are phosphorylated in vivo or whether S132/133
phosphorylation is functionally significant.
We found that phosphorylation of HDGF-S103 has a
significant effect on HDGF mitogenic activity. A substi-
tution mutation in HDGF to S103A to prevent phos-
phorylation nullified HDGF mitogenic activity, whereas
a S103D phospho-mimic mutation was constitutively
active, resulting in an increased mitogenic activity rela-
tive to wild type HDGF. This data would suggest that
one model of VSMC proliferation is that activation of
mitotic kinases results in phosphorylation of S103-
HDGF, leading to increased cell proliferation. As the
impact of the S103 mutants on the cell cycle was much
more profound than the wild type protein, this would
suggest that HDGF mitogenic function is dependent on
phosphorylation and not just dependent on the amount
of HDGF present.
Although the mechanism of phospho-S103-HDGF
function during mitosis is unclear, it is of interest that
another HDGF family member LEDGF, demonstrates
metaphase chromatin binding, requiring cooperative
interaction of the PWWP and AT-hook domains.
Although HDGF does not contain AT-hook domains, it
does bind DNA directly requiring a large 36 bp recogni-
tion sequence and requires the PWWP domain for
DNA binding [21]. It is unclear how phosphorylation
regulates this process either to induce a conformational
change to increase binding or enhance binding with a
chromatin binding protein. The HDGF PWWP domain
was recently shown to dimerize on heparin and whether
phosphorylation plays a role in potentially regulating
HDGF dimerization on chromatin via the PWWP
domain is an area of active research.
It is of great interest that a S282P mutation in the
DNA methyltransferase 3b (DNMT3b, also a PWWP
protein) gene results in the ICF syndrome (for immuno-
deficiency, centromeric instability, and facial anomalies)
[22]. This serine is 4 amino acids carboxy to the PWWP
domain in DNMT3b, and homologous to the location of
S103 in HDGF. The conservation of this serine in rela-
tion to the PWWP domain and its mutation associated
with a human disease, strongly implicates these serines
in the function of PWWP proteins.
Conclusion
HDGF is a mitotic phosphoprotein and phosphorylation
of S103 plays an important role in regulating the prolif-
eration of cells and the mitogenic function of HDGF.
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